CER 001
Alternative Names: CER-001; Cerenis HDL; Recombinant Human Apolipoprotein A-I; Recombinant Human Apolipoprotein A-I/Phospholipids complexLatest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Cerenis Therapeutics
- Developer ABIONYX Pharma; Academic Medical Center
- Class Antihyperlipidaemics; Apolipoprotein therapeutics; Cardiovascular therapies; Eye disorder therapies; Phospholipids; Recombinant proteins; Vascular disorder therapies
- Mechanism of Action Apolipoprotein A-I replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypoalphalipoproteinaemia
- Phase II Acute coronary syndromes; Acute kidney injury; Atherosclerosis
- Clinical Phase Unknown COVID 2019 infections
- Preclinical Uveitis
- No development reported Lecithin acyltransferase deficiency; Lipid metabolism disorders
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Acute kidney injury in USA (IV)
- 28 Dec 2024 No recent reports of development identified for clinical-Phase-Unknown development in Lecithin acyltransferase deficiency in Italy (Infusion)
- 24 Oct 2024 Efficacy data from the phase IIb RACERS trial in Acute kidney injury released by ABIONYX Pharma